Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Medical applications of transforming growth factor-beta.

Literature DB >> 15931280

Medical applications of transforming growth factor-beta.

Kathleen C Flanders¹, James K Burmester.

Abstract

Transforming growth factor-beta (TGF-beta) proteins and their antagonists have entered clinical trials. These multi-functional regulators of cell growth and differentiation induce extracellular matrix proteins and suppress the immune system making TGF-betas useful in treatment of wounds with impaired healing, mucositis, fractures, ischemia-reperfusion injuries, and autoimmune disease. In diseases such as keloids, glomerulonephritis and pulmonary fibrosis, excessive expression of TGF-beta has been implicated as being responsible for accumulation of detrimental scar tissue. In these conditions, agents that block TGF-beta have prevented or reversed disease. Similarly, in carcinogenesis, blocking TGF-beta activity may be valuable in stimulating an immune response towards metastasis. As these blocking agents receive approval, we will likely have new therapies for previously recalcitrant diseases.

Entities: Disease Gene

Mesh：

Substances：

Year: 2003 PMID： 15931280 PMCID： PMC1069016 DOI： 10.3121/cmr.1.1.13

Source DB: PubMed Journal: Clin Med Res ISSN： 1539-4182

107 in total

1. Locally delivered rhTGF-beta2 enhances bone ingrowth and bone regeneration at local and remote sites of skeletal injury.

Authors: D R Sumner; T M Turner; R M Urban; R M Leven; M Hawkins; E H Nichols; J M McPherson; J O Galante
Journal: J Orthop Res Date: 2001-01 Impact factor: 3.494

2. Safety and effect of transforming growth factor-beta(2) for treatment of venous stasis ulcers.

Authors: M C Robson; L G Phillip; D M Cooper; W G Lyle; L E Robson; L Odom; D P Hill; A F Hanham; G A Ksander
Journal: Wound Repair Regen Date: 1995 Apr-Jun Impact factor: 3.617

3. Alveolar ridge repair in a canine model using rhTGF-beta 1 with barrier membranes.

Authors: J D Ruskin; R Hardwick; D Buser; C Dahlin; R K Schenk
Journal: Clin Oral Implants Res Date: 2000-04 Impact factor: 5.977

4. The liver in transforming growth factor-Beta-1 (TGF-beta 1) null mutant mice.

Authors: A O Williams; A D Knapton; A Geiser; J J Letterio; A B Roberts
Journal: Ultrastruct Pathol Date: 1996 Sep-Oct Impact factor: 1.094

5. Role of transforming growth factor-beta signaling in cancer.

Authors: M P de Caestecker; E Piek; A B Roberts
Journal: J Natl Cancer Inst Date: 2000-09-06 Impact factor: 13.506

6. Domain-specific mutations in TGFB1 result in Camurati-Engelmann disease.

Authors: A Kinoshita; T Saito; H Tomita; Y Makita; K Yoshida; M Ghadami; K Yamada; S Kondo; S Ikegawa; G Nishimura; Y Fukushima; T Nakagomi; H Saito; T Sugimoto; M Kamegaya; K Hisa; J C Murray; N Taniguchi; N Niikawa; K Yoshiura
Journal: Nat Genet Date: 2000-09 Impact factor: 38.330

7. Topical transforming growth factor-beta3 in the prevention or alleviation of chemotherapy-induced oral mucositis in patients with lymphomas or solid tumors.

Authors: M C Foncuberta; P J Cagnoni; C H Brandts; R Mandanas; K Fields; H G Derigs; E Reed; S T Sonis; J Fay; F LeVeque; P Pouillart; H Schrezenmeier; R Emmons; E Thiel
Journal: J Immunother Date: 2001 Jul-Aug Impact factor: 4.456

8. Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease.

Authors: W A Border; N A Noble; T Yamamoto; J R Harper; Y u Yamaguchi; M D Pierschbacher; E Ruoslahti
Journal: Nature Date: 1992-11-26 Impact factor: 49.962

9. Antisense oligodeoxyribonucleotide inhibition of TGF-beta 1 gene expression and alterations in the growth and malignant properties of mouse fibrosarcoma cells.

Authors: M Spearman; W R Taylor; A H Greenberg; J A Wright
Journal: Gene Date: 1994-11-04 Impact factor: 3.688

10. Abnormal lung development and cleft palate in mice lacking TGF-beta 3 indicates defects of epithelial-mesenchymal interaction.

Authors: V Kaartinen; J W Voncken; C Shuler; D Warburton; D Bu; N Heisterkamp; J Groffen
Journal: Nat Genet Date: 1995-12 Impact factor: 38.330

21 in total

1. Enhanced angiotensin-converting enzyme 2 attenuates angiotensin II-induced collagen production via AT1 receptor-phosphoinositide 3-kinase-Akt pathway.

Authors: Le Bu; Shen Qu; Xiang Gao; J-J Zou; Wei Tang; L-L Sun; Z-M Liu
Journal: Endocrine Date: 2010-12-28 Impact factor: 3.633

2. Immunomodulator FTY720 induces myofibroblast differentiation via the lysophospholipid receptor S1P3 and Smad3 signaling.

Authors: Christina D Keller; Pilar Rivera Gil; Markus Tölle; Markus van der Giet; Jerold Chun; Heinfried H Radeke; Monika Schäfer-Korting; Burkhard Kleuser
Journal: Am J Pathol Date: 2007-01 Impact factor: 4.307

3. The NR3C1 Glucocorticoid Receptor Gene Polymorphisms May Modulate the TGF-beta mRNA Expression in Asthma Patients.

Authors: Michał Panek; Tadeusz Pietras; Artur Fabijan; Jan Zioło; Łukasz Wieteska; Beata Małachowska; Wojciech Fendler; Janusz Szemraj; Piotr Kuna
Journal: Inflammation Date: 2015-08 Impact factor: 4.092

4. Binding and biologic characterization of recombinant human serum albumin-eTGFBR2 fusion protein expressed in CHO cells.

Authors: Aini Wan; Yana Miao; Lin Peng; Yanfei Cai; Yun Chen; Yang He; Jianfeng Yang; Jian Jin; Huazhong Li
Journal: Bioengineered Date: 2017-02-17 Impact factor: 3.269

5. Construction of eukaryotic expression plasmid of hTGF-β3 and its inducing effect on differentiation of precartilaginous stem cells into chondroblasts.

Authors: Hongbo You; Anmin Chen; Tie Liu; Maopeng Wang; Guoliang Zhang
Journal: J Huazhong Univ Sci Technolog Med Sci Date: 2011-08-07